Current stock page

Financial Data

MRNA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

MRNAModerna, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$223.37−$7.98 (−3.45%)

Latest quote

  • Momentum
    93
  • Value
    50
  • Quality
    52
  • Risk resilience
    31
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$1.31B$145M$389M$678M$1.02B$142M$107M$956M
Gross Profit$995M$52M-$566M$226M$8M$23M$17M$217M
Operating Income$130M-$815M-$1.39B-$857M-$260M-$907M-$1.05B-$1.25B
Net Income$162M-$782M-$1.34B-$826M-$200M-$825M-$971M-$1.12B
EPS$0.4-$1.96-$3.4-$2.11-$0.51-$2.13-$2.52-$2.91
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$1.56B-$526M-$630M$951M-$847M-$919M-$1.04B$825M
Capital Expenditure-$47M-$37M-$62M-$39M-$33M-$3M-$127M-$522M
Free Cash Flow-$1.61B-$563M-$692M$912M-$880M-$922M-$1.16B$303M
Net Cash Provided By Operating Activities-$1.56B-$526M-$630M$951M-$847M-$919M-$1.04B$825M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$13.47B$10.96B$11.49B$12.34B$12.14B$12.01B$12.7B$14.14B
Total Debt$4.18B$1.29B$1.3B$1.92B$1.39B$741M$745M$747M
Cash And Cash Equivalents$1.2B$1.72B$1.91B$2.6B$1.13B$1.28B$1.62B$1.93B
Total Liabilities$6.63B$4.2B$4.08B$3.69B$2.81B$2.61B$2.64B$3.24B
Total Stockholders Equity$6.84B$6.76B$7.41B$8.65B$9.33B$9.4B$10.07B$10.9B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio16.923.212.422.261.021.141.041.25
P/S ratio35.47———————
Debt To Equity0.610.190.180.220.150.080.070.07
Free Cash Flow Yield-1.68%-5.63%-8.83%-10.51%-28.06%-32.68%-38.66%-29.64%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio16.923.212.422.261.021.141.041.25
P/S ratio35.47———————
Return On Equity-40.79%-46.61%-43.12%-32.62%-33.40%-30.89%-33.35%-32.67%
Debt To Equity0.610.190.180.220.150.080.070.07

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-31.59x
Pb13.1x
Revenue Growth Yoy29.23%
EPS Growth Yoy178.43%
Gross Margin28.00%
Operating Margin-116.04%
ROE-37.62%
ROIC-25.61%
Debt To Equity0.61
FCF Yield-2.16%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$223.37
Volume8.09M
RSI (14)49.72
MACD11.61
MACD signal13.83
MACD histogram-2.22
ADX (14)35.6
SMA (50)$201.67
SMA (200)$96.41
ATR (14)$19.84
Historical volatility (annualized)103.88%
Volume (20-day average)14.86M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score31/100
Beta2.33
Annual volatility194.57%
Max Drawdown-34.16%
Sharpe Ratio1.67
VaR (95%, 1-day)-6.99%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

MRNA Financial Data FAQ

What is Moderna, Inc.'s revenue?

Moderna, Inc.'s revenue is one of the core financial data points for MRNA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Moderna, Inc.'s revenue growing?

Revenue growth shows whether Moderna, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is MRNA's EPS?

MRNA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Moderna, Inc.'s net income?

Moderna, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Moderna, Inc. generate?

Free cash flow shows how much cash Moderna, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Moderna, Inc. have?

Cash and debt help frame MRNA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.